Hanna Ciepluch

Gdansk, PM, Poland

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 8 publications

Zanubrutinib Versus Bendamustine and Rituximab in Patients With Treatment-Naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Median 5-Year Follow-Up of SEQUOIA.

Zanubrutinib Versus Bendamustine and Rituximab in Patients With Treatment-Naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Median 5-Year Follow-Up of SEQUOIA.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: December 08, 2024

Available questionnaires do not cover important aspects of quality of life of patients with cutaneous T-cell lymphoma: evaluation of the quality of life of Polish patients with cutaneous T-cell lymphoma.

Available questionnaires do not cover important aspects of quality of life of patients with cutaneous T-cell lymphoma: evaluation of the quality of life of Polish patients with cutaneous T-cell lymphoma.

Journal: Postepy dermatologii i alergologii

Published: October 03, 2024

The Role of Lifestyle and Environmental Factors in the Pathogenesis of Multiple Myeloma.

The Role of Lifestyle and Environmental Factors in the Pathogenesis of Multiple Myeloma.

Journal: European journal of haematology

Published: August 24, 2024

The Real-World Evidence on the Fragility and Its Impact on the Choice of Treatment Regimen in Newly Diagnosed Patients with Multiple Myeloma over 75 Years of Age.

The Real-World Evidence on the Fragility and Its Impact on the Choice of Treatment Regimen in Newly Diagnosed Patients with Multiple Myeloma over 75 Years of Age.

Journal: Cancers

Published: May 30, 2023

Zanubrutinib versus bendamustine and rituximab in untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (SEQUOIA): a randomised, controlled, phase 3 trial.

Zanubrutinib versus bendamustine and rituximab in untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (SEQUOIA): a randomised, controlled, phase 3 trial.

Journal: The Lancet. Oncology

Published: January 31, 2022

The Outcomes of Ponatinib Therapy in Patients With Chronic Myeloid Leukemia Resistant or Intolerant to Previous Tyrosine Kinase Inhibitors, Treated in Poland Within the Donation Program.

The Outcomes of Ponatinib Therapy in Patients With Chronic Myeloid Leukemia Resistant or Intolerant to Previous Tyrosine Kinase Inhibitors, Treated in Poland Within the Donation Program.

Journal: Clinical lymphoma, myeloma & leukemia

Published: October 06, 2021

Zanubrutinib monotherapy for patients with treatment naïve chronic lymphocytic leukemia and 17p deletion

Zanubrutinib monotherapy for patients with treatment naïve chronic lymphocytic leukemia and 17p deletion

Journal: Haematologica

Published: May 29, 2020

Characteristics and outcomes of patients with multiple myeloma aged 21-40 years versus 41-60 years: a multi-institutional case-control study.

Characteristics and outcomes of patients with multiple myeloma aged 21-40 years versus 41-60 years: a multi-institutional case-control study.

Journal: British journal of haematology

Published: May 03, 2016

Showing 1-8 of 8

Last Updated: 09/26/2026